SIK2 and breast carcinoma: Decrease of PARP enzyme activity and phosphorylation of class-IIa HDAC4/5/7 were necessary and sufficient for the synergy observed between SIK2 inhibitors and PARP inhibitors for downregulating cancer cell growth in ovarian and breast cancer cell lines and xenografts.